Neogen (NASDAQ:NEOG - Get Free Report) was upgraded by investment analysts at Zacks Research from a "strong sell" rating to a "hold" rating in a note issued to investors on Wednesday,Zacks.com reports. Zacks Research also issued estimates for Neogen's Q1 2026 earnings at $0.05 EPS, Q2 2026 earnings at $0.08 EPS, Q3 2026 earnings at $0.08 EPS, Q4 2026 earnings at $0.08 EPS, FY2026 earnings at $0.30 EPS, Q1 2027 earnings at $0.08 EPS, Q2 2027 earnings at $0.09 EPS, Q4 2027 earnings at $0.09 EPS, FY2027 earnings at $0.36 EPS and FY2028 earnings at $0.35 EPS.
Several other research analysts have also recently commented on the company. Guggenheim cut their price target on Neogen from $13.00 to $10.00 and set a "buy" rating on the stock in a research note on Monday, June 30th. Piper Sandler cut their target price on Neogen from $6.40 to $5.00 and set a "neutral" rating on the stock in a research report on Tuesday, April 22nd. Finally, William Blair downgraded shares of Neogen from an "outperform" rating to a "market perform" rating in a research report on Tuesday, July 29th. One analyst has rated the stock with a Buy rating and three have issued a Hold rating to the company. According to MarketBeat.com, Neogen presently has a consensus rating of "Hold" and a consensus price target of $7.50.
Get Our Latest Analysis on Neogen
Neogen Stock Performance
Neogen stock opened at $5.60 on Wednesday. The company has a debt-to-equity ratio of 0.42, a current ratio of 3.32 and a quick ratio of 2.22. The firm's fifty day moving average price is $5.11 and its 200 day moving average price is $6.67. The company has a market capitalization of $1.22 billion, a price-to-earnings ratio of -1.11 and a beta of 1.79. Neogen has a 12-month low of $3.87 and a 12-month high of $17.95.
Hedge Funds Weigh In On Neogen
Several large investors have recently added to or reduced their stakes in the company. Bank Pictet & Cie Europe AG raised its holdings in shares of Neogen by 6.5% during the fourth quarter. Bank Pictet & Cie Europe AG now owns 132,000 shares of the company's stock worth $1,602,000 after purchasing an additional 8,000 shares during the period. Invesco Ltd. raised its stake in Neogen by 36.0% during the fourth quarter. Invesco Ltd. now owns 640,623 shares of the company's stock worth $7,777,000 after acquiring an additional 169,652 shares during the period. Raymond James Financial Inc. bought a new position in Neogen in the fourth quarter worth about $2,744,000. Barclays PLC lifted its holdings in Neogen by 29.6% in the fourth quarter. Barclays PLC now owns 475,365 shares of the company's stock worth $5,771,000 after acquiring an additional 108,612 shares during the last quarter. Finally, Guggenheim Capital LLC acquired a new position in Neogen in the fourth quarter valued at approximately $147,000. 96.73% of the stock is currently owned by institutional investors.
Neogen Company Profile
(
Get Free Report)
Neogen Corporation, together with its subsidiaries, engages in the development, manufacture, and marketing of various products and services dedicated to food and animal safety worldwide. It operates through two segments, Food Safety and Animal Safety. The Food Safety segment offers diagnostic test kits and related products to detect dangerous and unintended substances in food and animal feed, including foodborne pathogens, spoilage organisms, natural toxins, food allergens, genetic modifications, ruminant by-products, meat speciation, drug residues, pesticide residues, and general sanitation concerns; and AccuPoint Advanced rapid sanitation test to detect the presence of adenosine triphosphate, a chemical found in living cells, as well as provides genomics-based diagnostic technology and software systems that help testers to objectively analyze and store their results and perform analysis on the results from multiple locations over extended periods.
Further Reading
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Neogen, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Neogen wasn't on the list.
While Neogen currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Thinking about investing in Meta, Roblox, or Unity? Enter your email to learn what streetwise investors need to know about the metaverse and public markets before making an investment.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
MarketBeat All Access